MUSTANG BIO, INC. cotiza a 0.41 USD y tiene una capitalización bursátil de $3M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for …
| Periodo | 2025-03 | 2024-11 | 2024-08 | 2024-05 |
|---|---|---|---|---|
| Real | $3.63 | $-2.00 | $-12.00 | $-23.00 |
| Estimado | $-8.00 | $-6.50 | $-7.00 | $-11.00 |
| Sorpresa | +145.4% | +69.2% | -71.4% | -109.1% |
| Métrica | MBIO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -20.2% | -40.4% | +20.2% |
| ROA | -10.9% | -32.0% | +21.1% |
| Current Ratio | 2.22 | 2.84 | -0.62 |
| Debt / Equity | — | 0.28 | — |